Effect of a Single Intravitreal Ranibizumab Injection on Diabetic Macular Edema in Patients Who Discontinued Treatment

Abstract

Objective: To evaluate the effect of a single dose of ranibizumab in patients with diabetic macular edema who discontinued treatment. Methods: One eye of 85 patients with diabetic macular edema who discontinued treatment after a single injection of ranibizumab was studied. Best corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT), and optical coherence tomography imaging were evaluated retrospectively. Changes in BCVA, IOP, CMT, and their correlations with the follow-up period were statistically analyzed. Results: At baseline, the mean BCVA was 0.26 ± 0.20 (Snellen equivalent [SE]) and CMT was 469.04 ± 144.6 µm. After a mean period of 6.12 ± 2.46 months, mean BCVA was 0.316 ± 0.23 SE and CMT was 403.07± 139.7 µm. There was a statistically significant increase in BCVA and decreased in CMT (p= 0.02, p< 0.01, respectively), whereas mean IOP values did not significantly change (p=0.24). There was no statistically significant correlation between the follow-up duration and BCVA or CMT (p=0.928 and p=0.992, respectively). Conclusions: Visual outcome and CMT thickness were still superior to those before treatment even after a single ranibizumab injection.

A retrospective, non-randomized, clinical review on the effect of single-dose biosimilar Razumab injection in diabetic macular edema

“…This result was similar to earlier studies. (Yumusak et al, 2016). The AS examination showed that on the day of injection, 26 patients developed suprachoroidal haemorrhage (SCH), but on day 7, 0 patients developed SCH because it is a selflimiting condition.…”